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Abstract:  
OBJECTIVES: The primary aim of this study was to investigate whether ovarian cancer patients 
in Kentucky are more likely to have multiple primary and synchronized primary cancers 
compared to Non-Kentucky SEER registry cancer patients. A secondary aim of the study was to 
determine if there are other factors that may be associated with an increased risk of having 
multiple primary and synchronized cancer as well as determining if having multiple primary and 
synchronous cancer diagnoses changes survival rates in ovarian cancer patients. Additionally, 
another objective was to identify the most frequently observed subsequent and synchronous 
cancers sites that are diagnosed in ovarian cancer patients within Kentucky.  
METHODS: The data for this retrospective, population-based cohort study of 72,491 primary 
ovarian cancer patients were obtained from the Kentucky Cancer Registry. To be included in the 
study population, the patients from Kentucky and Non-Kentucky areas within the SEER registry 
had to have been diagnosed between January 1, 2000 and December 31, 2014. Subjects were 
classified as a multiple primary cancer case based on whether they were diagnosed with a second 
primary cancer in addition to their first primary of ovarian cancer within the years 2000-2014. 
Subjects were classified as a synchronous cancer case if they were diagnosed with their 
secondary cancer diagnosis within 6 months or less or their first diagnosis. Logistic and Cox 
regression were utilized to identify factors associated with multiple primary cancer and 
synchronized cancer. 
RESULTS: After much investigation, the focus of this analysis turned to early stage disease and 
the comparison to all stage for multiple primary and synchronous ovarian cancers. This is due to 
the fact that in the analysis, an interaction was found between early stage ovarian cancer and the 
location variable with Kentucky having 1.25 greater odds of being diagnosed with early stage 
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ovarian cancer (adjusted OR=1.25 [95% CI (1.04, 1.5)], p=0.0364).  
There were statistically significant differences in the distribution of early stage and late 
stage cancer cases in patients who had multiple primaries but not for synchronous cancers 
between Kentucky and SEER (early stage multiple primary p=0.0071, early stage synchronous 
p=0.1008). There was also a significant association between multiple primary cancer status 
between Kentucky and SEER with Kentucky patients having a 1.23 times the odds of developing 
multiple primaries compared to SEER patients; adjusted OR=1.23, [95% CI (1.02, 1.47)].  
 The Cox proportional hazard model for multiple primary cancer adjusted for early stage 
revealed that there were no statistically significant differences between Kentucky and SEER in 
regards hazard of being diagnosed with a multiple primary cancer (adjusted OR=1.04 [95% CI 
(0.91, 1.19)]). 
There were no survival differences seen between Kentucky and SEER for multiple primary cases 
(log-rank test=0.7093). There were also no survival differences seen between Kentucky and 
SEER for synchronous cancer cases (log-rank test: 0.8419). Survival curves were also 
constructed for early stage of disease for both multiple primary and synchronous cancer cases 
and no differences were seen (log-rank test: 0.5805 and log-rank test: 0.9833). Survival 
differences were seen when comparing Kentucky and SEER for both multiple primary and 
synchronous cancer cases with Kentucky having much lower survival in both cases (log-rank 
test: 0.0329 and log-rank test: 0.0353).         
CONCLUSIONS:  Based on the results from the Cox proportional hazard model, primary 
ovarian cancer patients living in Kentucky are not at a greater risk of having multiple primary 
cancers than those residing in Non-Kentucky SEER areas, regardless of stage of disease. When 
observing the results from the logistic model for early stage of disease, the results indicate that 
Commented [FS1]: Hanging clause 
Commented [FS2]: hazard 
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Kentucky is at a greater risk for developing early stage multiple primary cancers in comparison 
to Non-Kentucky SEER. This difference could be due to the fact that a large number of 
observations had to be deleted due to the fact that date of diagnosis for the secondary cancer for 
these patients could not be obtained because the information was not in the database. High risk 
groups identified in this study are women who were diagnosed in earlier years, were older, white, 
single, lived in an urban area, had grade I cancer, and those who had sex chord-stromal tumors. 
Further analyses are needed to determine the definitive implications of the higher proportions of 
early stage cancer within Kentucky.  
  
Commented [FS3]: why couldn’t you get date of 
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Introduction: 
  Ovarian cancer is the leading cause of deaths from gynecologic cancers. An estimated 
14,080 ovarian cancer deaths will occur in 2017. Ovarian cancer accounts for about 5% of the 
cancer deaths among women. Even though this is a small percentage, ovarian cancer is an 
extremely aggressive and very fatal cancer. The 5-year relative survival rate for ovarian cancer 
is relatively low (46%) and this is due to the fact that most patients (60%) are diagnosed with 
distant-stage disease, for which survival is 29%. For the 15% of patients diagnosed with 
localized disease, 5-year survival is 92%. Survival varies significantly by age, with women 
younger than 45 much more likely to survive 5 years than women 75 and older (77% versus 
20%).1 Although survival for women with ovarian cancer has improved over the past few 
years, this has allowed for the opportunity for increases in the occurrence of second malignant 
neoplasms.18  
    It is estimated that on January 1, 2005 within the US that there were 880,300 cancer 
survivors who had been diagnosed with more than one cancer.28 Second primary cancers 
diagnoses are seen in about 15% of cancer survivors overall, which can result in increased 
morbidity and mortality.20 A study published in the 2009 edition of the European Journal of 
Cancer Prevention showed a significant excess risk of second neoplasms in women who were 
diagnosed with invasive or borderline ovarian cancers. Most of this excess was found to be 
attributable to synchronously diagnosed neoplasms (cancers diagnosed in the same time period 
as the index ovarian cancer).16 Another study published in 2007 in the Journal of Modern 
Pathology found that ovarian cancer patients had an increased risk for developing synchronous 
cancers.19 
Commented [FS4]: on 
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    For most epidemiological studies, cases are classified as multiple primary malignancies if 
they arise in different sites or they have a different histology or morphology type. This definition 
helps avoid any misclassification of tumors that are not multiple primaries as such.35 For this 
study, the SEER database defines multiple primaries as follows: 1) two or more separate 
neoplasms in different topographic sites 3) certain conditions that are characterized by multiple 
tumors 3) lymphomas, which often involve multiple lymph nodes or organs at diagnosis 4) two 
or more neoplasms of different morphology arising in the same site 5) a single neoplasm 
involving multiple sites whose precise origin cannot be determined.25In most cases, researchers 
define synchronous cancers as cancers that are diagnosed less than 6 months from first cancer 
diagnosis.  One study in particular defined synchronous cancer cases as “2 diagnoses at once or 
less than 6 months of the first cancer diagnosis”.13  
  According to an article published in the 2003 edition of the Journal of American Cancer 
Society, multiple cancer diagnoses may be caused by inherited or acquired cellular lesions or 
deficiencies, that can be caused by environmental exposures to carcinogens. The article also 
states that these diagnoses can be linked or completely independent of their first primary 
malignancy.7 Additionally, ovarian tumors as well as breast, endometrial, and colon cancers 
have been shown to be linked reproductive hormones. Both genetic and other reproductive 
factors have also been shown to contribute to increased risk of second primary malignancies 
especially breast, colorectal, and melanoma.16 None of these factors were assessed in this 
study.  
    Results from a study published in the 2015 issue of the Journal of Medicine (Baltimore) 
demonstrated that that the risk of second primary malignancy is significantly higher in patients 
Commented [FS5]: of 
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diagnosed with ovarian cancer. Age, chemotherapy, and radiotherapy (treatment) were all 
independent risk factors for second primary malignancies in this population.11  
    Although research has been conducted regarding treatment and risk factors for ovarian 
cancer, very little has been done to assess the status of ovarian cancer within Kentucky 
compared to other areas in regards to risk of second primary diagnosis or time to second cancer 
diagnosis. While rates are particularly low within Kentucky compared to many other 
cancers,6,29 ovarian cancer still remains at the top of the list for being the cause of more deaths 
in women than any other gynecologic cancer. Additionally, in 2016 Kentucky was ranked the 
highest within the Unites States for cancer burden.3 Comparing Kentucky to all Non-Kentucky 
SEER populations is also important due to the major differences in the areas. Kentucky is a 
largely rural population in comparison to the more urban populations that exist in the other 16 
SEER regions in this study. Kentucky has also been identified as having major health disparities 
and  has been designated as a special population by the National Cancer Institute.26 Therefore, it 
is especially important to determine whether case distribution and survival differences do exist 
from cancers like ovarian cancer in Kentucky compared to the rest of the SEER registered 
population.  
Also, due to generally low survival rates in ovarian cancer patients, second primary 
diagnoses are not usually studied. The fact that other studies have found an increased risk for 
second primary malignancies for ovarian cancer patients and that historically Kentucky has 
been at an increased risk incident cancer diagnoses, it is important to determine if there are 
differences in the distribution of multiple primary cancer cases, risk factors, and survival 
between the Kentucky population and all other SEER registry population overall.  Since 
ovarian cancer patients have also been shown to be at an increased risk for developing 
Commented [FS6]: huh? 
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synchronous cancer, we decided to expand our investigation to assess if there were these 
differences for synchronous cancers as well.  
Methods: 
Study Population and Design  
    This was a retrospective, population-based cohort study of 72,491 first primary ovarian 
cancer patients, 3671 patients from Kentucky and 68,820 patients from overall SEER (all areas 
excluding Kentucky). These patients were aged 20 years and older, that all had previously been 
diagnosed with a primary of ovarian cancer between January 1, 2000 and December 31, 2014. 
Ovarian cancer patients in Kentucky were chosen as the target population, due to the fact that 
ovarian cancer is the highest in mortality rates for gynecologic cancers. Additionally, Kentucky’s 
history as far as cancer burden and mortality in general makes the area an ideal population to 
study.  The study population was drawn from the Kentucky Cancer Registry, which is both an 
NCI Surveillance, Epidemiology, and End Results (SEER) cancer registry and a CDC National 
Program of Cancer Registries (NPCR) participant.32     
Subjects were classified as a multiple primary cancer case based on a sequence number in 
the database and whether they received their secondary cancer diagnosis in between 2000-2014 
after having a first primary diagnosis of ovarian cancer. To be classified as a synchronous cancer 
case, subject had to have been diagnosed with a second cancer in 6 months or less from their first 
diagnosis of ovarian cancer. Additionally, subjects were classified as a non-synchronous case if 
they had only one primary diagnosis or if they had a second cancer diagnosis in greater than 6 
months from their first diagnosis of ovarian cancer. A review of previous literature was 
conducted and the grouping of histology codes was based on the results found from previous 
studies and guidelines.9, 15, 37 
Commented [FS8]: a sequence number 
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    The subjects from both Kentucky and SEER registered patients (non-Kentucky areas) 
were followed to determine if they had differences in survival based on their multiple primary 
and synchronous cancer status as well as how important risk factor variables contributed to these 
differences. The primary hypothesis of this study was that Kentucky patients would have greater 
proportions of multiple primary and synchronous cancers as well as a decreased overall survival 
when compared to other SEER registered patients. The study also examined other factors 
associated with the development of multiple primary and synchronous cancers in ovarian cancer 
patients. 
    This study was approved by the Institutional Review Board of the University of 
Kentucky (# 43510) and received Exemption Certification for Protocol No. 43510. 
Data Analysis 
    SEER*Stat version 8.3.4 was used to identify eligible patients to be included in the 
study.31 Statistical analyses were carried out using SAS version 9.4. Descriptive analyses for 
univariate distributions were reported as sample size, percent, means, medians, standard 
deviations, quartiles, minimum and maximum values were examined for continuous variables. 
For categorical variables, frequencies and percentages were calculated. Results were examined 
by main exposure (concurrence cancer diagnosis status), in both Kentucky and all other SEER 
registry areas and a comparison was made between the two groups. Using non-Kentucky SEER 
status as the reference group, bivariate distributions between risk factors and exposure were 
assessed using chi-square p-value and Fisher’s Exact for those cell counts that were less than 5 in 
magnitude. Logistic regression analyses were conducted to examine whether Kentucky status is 
associated with multiple primary and synchronized cancer status while controlling for other 
factors.  
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    A Cox proportional hazard model was utilized in order to determine if there was an 
association between potential risk factors as well as the region in which the patients lived and the 
likelihood of developing multiple primary cancers.  Kaplan-Meier method was used to produce 
survival curves. The log-rank P-value was utilized to assess differences between the estimated 
survival curves. All tests were evaluated using a two-sided significance level of 5%. 
Results:  
Descriptive Statistics/Univariate Findings 
   There were 3,671 women from Kentucky and for women in non-Kentucky SEER there 
were 68,820 in the sample size. Additionally, the results show that from 5,377 patients diagnosed 
as a multiple primary ovarian case, that 2,489 cases manifested as a synchronous malignancy 
(46.3%) which is consistent with the current literature.14 Results from Table 1 show that of 
women in Kentucky and SEER, the majority of the women were in the aged 50-64 (32.8% and 
34.6%). As year of diagnosis increased, the number of cases of ovarian cancer for Kentucky and 
for SEER the cases decreased and then increased again up to 2014. The majority of the women 
were white with 95.2% in Kentucky and 82.7% in SEER. For Kentucky, 30.8% of women lived 
in an Appalachian region. Appalachian status was not calculated for women in non-Kentucky 
SEER due to the fact that only 2 out of 16 regions included in the Non-Kentucky SEER group 
had Appalachian regions. Within Kentucky, the distribution of patients in rural and urban areas 
was divided almost evenly with 53.6% of the women living in urban areas. In SEER, 90.2% of 
the women were living in urban areas. In both Kentucky and SEER, most of the women were 
married (44.6% and 48.2%). Of all of the cases in Kentucky and SEER, only 7.8% and 7.4% 
were multiple primaries and synchronous cases consisted of 3.8% and 3.4% of the sample size. 
Most of the women had late stage disease with 54.9% in Kentucky and 57.1% in SEER. In both 
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Kentucky and SEER,  of the women with known grade of disease, most of the women had grade 
III disease (Kentucky: 27.4% and SEER: 30.2%). Finally, the most frequently observed histology 
type in both areas was epithelial tumors (Kentucky: 61.8% and SEER: 64.2%).  
Multiple Primary Cancer Diagnoses 
     Table 2 demonstrates the distribution of multiple primary cancers within each region by 
stage. Within Kentucky, 15.1% of the 285 multiple primary cancer cases were early stage 
compared to the 12.3% early stage multiple primary cases in Non-Kentucky SEER. Additionally, 
within early stage of disease, there were found to be statistically significantly differences 
between Kentucky and SEER for distributions of multiple primary cancer cases (p= 0.0071). 
There were no statistically significant differences for multiple primary cases for late stage 
disease. 
    Table 3 shows that of the women from Kentucky, 7.8% had multiple primary cancers 
compares to 7.4% from the SEER areas. Most of these women were aged 50-64 (40.4% in KY 
and 41% in SEER), were white (95.4% in KY and 85.1% in SEER), lived in an urban area 
(55.4% in KY and 91% in SEER), were married (44.9% in KY and 52.2% in SEER), had early 
stage of disease (56.1% in KY and 45.1% in SEER), had grade III disease (32.6% in KY and 
30.7% in SEER), and had epithelial tumors (71.9% in KY and 74.2% in SEER). Additionally, for 
those women with multiple primary cancers in Kentucky, 67.4% were living in Non-Appalachian 
areas.  
 
 
Commented [FS9]: Table 2 should come before Table 
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Synchronous Cancer Diagnoses 
Table 2 also shows the distribution of synchronous cancers within each region by stage of 
disease. Within Kentucky, 7.4% of the 285 multiple primary cases were early stage synchronous 
cases compared to the 6.1% early stage synchronous cases in Non-Kentucky SEER. Also, within 
early stage of disease, there were no statistically significantly differences between Kentucky and 
SEER for distributions of synchronous cancer cases (p= 0.0950). Additionally, there were no 
statistically significant differences for synchronous cases for late stage disease. 
  Table 4 depicts the results for the distribution of synchronous cancer cases by location. 
From the total sample size and for patients with synchronous cancer diagnoses, 3.9% were from 
Kentucky and 3.5% were from SEER areas. Similar to the women with multiple primaries, of the 
synchronous cases most women were aged 50-64 (34.5% in KY and 39.2% in SEER), were 
white (97.1% in KY and 84% in SEER), lived in an urban area (54.7% in KY and 91.8% in 
SEER), were married (46.8% in KY and 49.7% in SEER), had early stage of disease (54.7% in 
KY and 47.5% in SEER), had grade III disease (30.9% in KY and 24.9% in SEER), and had 
epithelial tumors (73.4% in KY and 71.8% in SEER). Additionally, for those women with 
synchronous cancer diagnoses in Kentucky, 66.2% were living in Non-Appalachian areas.  
Most Frequently Observed Cancer Sites for Multiple Primary and Synchronous Ovarian 
Cancer Cases  
    The most frequently observed type of multiple primary diagnosis was uterine cancer 
(31.2% in KY and 56.3% in SEER), followed by breast (13.7% in KY and 7.5% in SEER) lung 
and bronchus (4.9% in KY and 2.4% in SEER), and ovary (second primary malignancy but same 
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site as first primary) (4.6% in KY and 1.4% in SEER). For synchronous cancer, the most 
frequently observed type of secondary cancer was uterine (61.2% in KY and 56.3% in SEER), 
ovarian (7.2% in KY and 5.0% in SEER), and breast cancer (6.5% in KY and 7.5% in SEER). 
There were no significant differences in the distribution between Kentucky and SEER for 
multiple primary cancers (p=0.4992) but there were differences found among patients with 
synchronous cancers (p=0.0443). 
Findings from Logistic Regression Models and Patient Survival  
    After much investigation, the focus of analysis turned to early stage disease and the 
comparison to all stage ovarian cancer. This is due to the fact that in the analysis, an interaction 
was found between early stage ovarian cancer and the location variable with Kentucky having 
1.25 greater odds of being diagnosed with early stage ovarian cancer (adjusted OR=1.25 [95% CI 
(1.04, 1.5)], p=0.0364). This lead to the logistic modeling of both multiple primary and 
synchronous cancer cases adjusting for early stage of disease. Early stage disease was classified 
as stage I and stage II ovarian cancer and late stage was classified as stage III and stage IV. 
Unknown stage was not included within the logistic or Cox proportional hazard models.  
There were statistically significant differences in the distribution of early stage and late 
stage cancer cases between Kentucky and SEER but only in patients with multiple primary 
cancers (Table 2- early stage multiple primary p=0.0071) Early and late stage synchronous 
cancers were not statistically different between Kentucky and SEER (Table 2- early stage 
synchronous p=0.0950.  
    Results from the logistic model for early and late stage in Table 6 indicate that there were 
no significant differences in the odds of developing multiple primary cancers between Kentucky 
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and SEER (adjusted OR= 1.06 [95% CI (0.93, 1.22)] p=0.4008).  
   Table 6 also shows the results from the logistic model with multiple primary cancers for early 
stage only. When adjusting for early stage, there were significant differences in the odds of 
developing multiple primary cancers between Kentucky and SEER, with Kentucky patients 
having a 1.23 greater odds of developing early stage multiple primaries compared to SEER 
patients; adjusted OR=1.23, [95% CI (1.02, 1.47)]. Women with early stage disease and aged 65-
74 had a 1.16 increase in odds adjusted OR=1.16, [95% CI (1.08, 1.33)]. and those aged 75+ had 
a 14% decrease in odds adjusted OR=0.86, [95% CI (0.72, 1.03)] of having a multiple primary 
diagnosis when compared to women aged 20-49. These two age groups were the only ones with 
statistically significant differences. For early stage disease, the year these women were diagnosed 
modeled as a continuous variable in the logistic model also proved to be statistically significant 
(adjusted OR=0.93 [95% CI (0.94, 0.96)], p = <0.0001). There were no significant results 
regarding race in the model except for the unknown category. When compared to patients with 
grade I disease, patients with grade II, grade III and grade IV proved to be statistically significant 
in the model with grade II patients having an 6% decrease in odds (adjusted OR=0.94, [95% CI 
(0.83, 1.06)]), grade III patients having a 31% decrease in odds (adjusted OR= 0.69 [95% CI 
(0.63, 0.77)]), and grade IV patients having a 37% decrease in odds (adjusted OR=0.63 [95% CI 
(0.56, 0.72)]) of being diagnosed with multiple primary cancers. Additionally, when compared to 
patients with epithelial tumors, patients with sex-chord-stromal and germ cell tumors had results 
that were statistically significant. Patients with sex-chord-stromal tumors had 1.06 times 
increased odds (adjusted OR=1.06 [95% CI (0.93, 1.22)]) and patients with germ cell tumors had 
a 72% decrease in odds of being diagnosed as a multiple primary cancer (adjusted OR=0.28 
[95% CI (0.20 0.40)]).   
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    Table 7 shows the logistic models for early and late stage synchronous cancer cases did 
not show statistically significant results regarding the location of the patient (adjusted OR 1.14 
[95% CI (0.94, 1.38)] p=0.1949). Table 7 also showed results for the adjusted model for 
synchronous cancer which was adjusted for early stage of disease. There were no significant 
associations between synchronous cancer status between Kentucky and SEER in the adjusted 
model; adjusted OR=1.133, [95% CI= (0.943, 1.361)] p=0.1008. 
There was no Cox proportional hazard analysis conducted on synchronous cancers due to 
the fact that it was dichotomous at 6 months and this was a very short amount of time for follow-
up.  
      A Cox proportional hazard model was conducted to allow for the control of variables 
that could potentially be confounding as well as allowing the censoring cases of death due which 
otherwise would not have been possible with a logistic regression model only. Again, the focus 
of this analysis was early stage verses all stage cancer cases due to the previously mentioned 
interaction that was found. The Cox proportional hazard model for multiple primary cancer for 
early and late stage in Table 8 showed that there were no statistically significant differences 
between Kentucky and SEER in the hazard of being diagnosed with a multiple primary cancer 
(adjust OR=1.06 [95% CI (0.92, 1.22)]).  
    There were also no differences between Kentucky and SEER seen in Table 8 for the Cox 
proportional hazard model for multiple primary cancer adjusted for early stage in regards to the 
hazard of being diagnosed with a multiple primary cancer (adjust OR=1.04 [95% CI (0.91, 
1.19)]). There were statistically significant results in the model adjusting for early stage with 
regards to age groups 50-64 and 65-74. Women aged 50-64 had a 1.14 increase in hazards of 
death compared to women who were aged 20-49 and women who were aged 65-74 had a 1.19 
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increase in hazards of death when compared to women aged 20-49. Year of diagnosis was also 
statistically significant in this model ((adjusted OR=1.04 [95% CI (0.91, 1.19)] p=<0.0001). For 
early stage patients compared to white women, black women had a 12% decrease (adjusted 
HR=0.88 [95% CI (0.78, 0.99)]) and other women (American Indian/ AK Native, Asian/Pacific 
Islander) had a 14% decrease in hazards of being diagnosed as a multiple primary case (adjusted 
HR=0.86 [95% CI (0.77, 0.96)]). There were no statistically significant results for urban status 
within the model.  
    When compared to being single, married women with early stage cancer  had a 16% 
decreased hazard (adjusted HR=0.84 [95% CI (0.77, 0.91)]), separated or divorced women had a 
14% decreased hazard (adjusted HR=0.86 [95% CI (0.77, 0.97)]), and widowed women had a 
15% decreased hazard of being diagnosed with a multiple primary cancer (adjusted HR=0.85 
[95% CI (0.76, 0.96)]). Compared to women with grade I disease, women with early stage 
disease and grade III had a 31% decrease (adjusted HR=0.69 [95% CI (0.63, 0.77)]) and women 
with grade IV had a 40% decrease in hazards of having a multiple primary cancer diagnosis 
(adjusted HR=0.60 [95% CI (0.53, 0.69)]). When compared to women with epithelial tumors, 
women with early stage disease and sex chord-stromal tumors had a 1.13 increase (adjusted 
HR=1.13 [95% CI (1.02, 1.26)]) and women with germ cell tumors had a 64% decreased hazard 
of developing multiple primary cancer (adjusted HR=0.36 [95% CI (0.27, 0.48)]). 
    There were no survival differences seen between Kentucky and SEER for multiple 
primary cases (log-rank test=0.7093). There were also no survival differences seen between 
Kentucky and SEER for synchronous cancer cases (log-rank test: 0.8419). Survival curves were 
also constructed for early stage of disease for both multiple primary and synchronous cancer 
cases and no differences were seen (log-rank test: 0.5805 and log-rank test: 0.9833). Survival 
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differences were seen when comparing Kentucky and SEER for both multiple primary and 
synchronous cancer cases with Kentucky having much lower survival in both cases (log-rank 
test: 0.0329 and log-rank test: 0.0353). 
Discussion: 
    Research has shown that health disparities do exist within Kentucky and given the special 
populations designation by the National Cancer Institute for this area27 and that it is especially 
important to assess whether case distribution and survival differences do exist from cancers like 
ovarian cancer in Kentucky compared to the rest of the SEER registered areas.  
    To our knowledge, this is the first study that has examined the risk factors and survival 
differences for multiple and synchronous ovarian cancer cases within this population. Where 
overlap in findings from other studies existed, our findings were similar to the findings of 
previous studies that used SEER guidelines to define multiple primary and synchronous cancers. 
Location variable 
 
    This study showed that when adjusting for early stage of disease, there were significant 
differences between Kentucky and SEER with regards to risk of developing early stage multiple 
primary malignancies but only within the logistic regression model. In the Cox regression model 
for multiple primary malignancies, the results for early stage of disease was not statistically 
significant. This is most likely due to the fact that there was a number of observations that had to 
be deleted because no date of second diagnosis or other follow-up information was available on 
these patients. Additionally, a lot of these patients may have died or just not had enough time to 
develop other primary cancers. Given the fact that the odds ratio in the logistic model and the 
hazard rate in the Cox regression for early stage cancer within Kentucky are both greater than 
one, the results might have otherwise been significant. Within Kentucky, there were a greater 
         
20 
 
proportion of early stage multiple primary and synchronous cancers when compared to Non-
Kentucky SEER. This may be due to the Ovarian Cancer Screening Program Trial that has been 
ongoing since 1987 at the University of Kentucky. Their use trans-vaginal sonography along 
with serum CA-125 testing has proved to be incredibly effective for earlier detection of ovarian 
cancer.33,35 A study published in 2011 in the Journal of Obstetrics & Gynecology evaluating long 
term survival of the women within the trial found results that indicate that the annual screening 
for at risk women caused a decrease in the stage at detection and site-specific ovarian cancer 
mortality when compare to women from the same area who did not have annual screenings.33 
These results give indications that patients in Kentucky are getting diagnosed at an earlier stage 
and therefore have longer survival and more opportunity to develop secondary cancers.  
Age 
 
    Results from this study revealed when adjusting for early stage of disease that there was 
an increased risk for developing multiple and synchronous after a first primary of ovarian cancer 
if patients were aged 50-64 and 65-74. There was a decrease in risk in the 75+ group and this 
could be due to the lower survival in this age group and that they did not have time to develop a 
secondary cancer. For patients diagnosed with synchronous cancer along with the first primary 
ovarian cancer, there was also a decrease in odds in for women aged 75+. In the same previously 
mentioned article published in the North American Association of Central Cancer Registries 
Journal, patients with multiple primary ovarian cancers were found to be older in comparison to 
those who had a single primary.3 Interestingly, two other studies Suris-Swartz et al. and Sheu et 
al. found opposite results for patients with multiple primary ovarian cancers. These studies (who 
reported only on synchronous tumors) were found to be younger. 26, 30 
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No other statistically significant results were found within age for women who had 
synchronous cancers.   
Year of diagnosis  
    The results showed statistically significant results for both multiple primary and 
synchronous cases. The overall trend for multiple primary cancers was a decrease in cases as the 
years increased from 2000-2014. This indicates that patients diagnosed in earlier years were 
more likely to develop other cancers simply because they survived longer and had greater 
opportunity.  For synchronous cancers cases, the number of cases increased as the years 
increased. This can most likely be attributed to increased screening and diagnosis methods. 
While there is still not a great screening method for ovarian cancer, over the past few years there 
has been an increase in surveillance and knowledge about risk factors for the disease. Significant 
progress has been made especially in regards to the diagnosis and treatment of women with 
ovarian cancer in the last few years and the effects are just now being observed.21 This can 
particularly be seen in this study in the Cox regression model for multiple primary cancers; the 
odds ratio for year of diagnosis increased which also indicates an increase in synchronous 
cancers in recent years. This could mean that most of these women who are being screened in 
recent years, are having their cancers diagnosed due to better screening methods in the past few 
years. 
Race 
    Interestingly, the results from the logistic models for early stage synchronous and 
multiple primary malignancies did not indicate statistical significance but the results from the 
Cox regression model for multiple primary cancers did. Overall, the results were consistent with 
previously mentioned literature that have found that the majority of ovarian cancer patients are 
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white females.11 Also, the majority of women in Kentucky were white while within SEER there 
was more of mixture of races in the population. This is because Kentucky is not as diverse of a 
population in regards to race when compared to the rest of the SEER registry.  
Marital status 
    Marital status was not significant within the logistic models for multiple primary and 
synchronous cancers but it was significant in the cox regression model for multiple primary 
cancers for both early stage only and early and late stage. The overall trend demonstrated that 
when compared to single women, married, separated/divorced, and widowed women had a 
decrease in hazards of being diagnosed as an early stage multiple primary.   
Grade 
 Grade of disease was consistently significant in both the logistic models for multiple 
primary and synchronous cancers as well as in the Cox regression model for multiple primary 
cancer. Generally, earlier grade of disease is associated with slower growing cancers and 
generally better survival.2 These results are consistent with previous findings that these patients 
are may be surviving longer and therefore have greater opportunity to develop other cancers.  
Histology 
    Patients with sex chord-stromal tumors consistently had an increase in odds of being 
diagnosed with multiple and synchronous cancers. Also within the Cox proportional hazard  
model for multiple primary cases, patients with this histology type were more likely to be 
diagnosed at an earlier stage of disease. It is interesting because this histology of ovarian cancer 
is less common than other histology types but also tends to present as low-grade and less 
aggressive.10, 13 One study published in 2009 found that improved survival in sex chord-stromal 
ovarian tumors and attributed the results to a stage-shift toward more favorable stages at 
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diagnosis and advances in treatment such as improved surgery with no residual tumors.13 These 
result align with the conclusions that this increase in survival gives these patients more time to 
develop secondary cancers and makes them at higher for multiple primary cancer diagnoses.  
Strengths 
The current descriptive study provided an opportunity to study multiple primary and 
synchronous ovarian cancers in a large and diverse population. Using a standard method, 
population‐based data were collected from the SEER registry within the United States 
population during the period 2000-2014. The large number of cases (72,491) allowed us to 
examine multiple primary and synchronous ovarian cancer cases and assess important risk 
factors and to compare these descriptors among locations to see if there were any differences.  
Limitations 
    One of the important limitations in this study has to do with the data source. The use of 
SEER registry data is limiting at times due to the fact that all cases and information may not be 
captured. In the case of this study in particular, all synchronous or multiple primary cancer cases 
may not be included in the data due to patients moving away to other areas or not receiving 
information from hospitals on the patient’s current status (treatment, current disease status, etc.) 
In this analysis, the biggest issue with the data was in using a Cox proportional hazard analysis in 
order to model the multiple primary cancer cases. Due to the lack of information on vital status 
and other important factors, a large portion of the patients had to be deleted. This occurred 
because many patients who did have multiple primaries did not have the date of diagnosis of 
their second cancer diagnosis or other follow-up information was not able to be obtained. 
Ultimately, even though the odds ratio for the location variable showed that Kentucky was at an 
increased risk for developing multiple primary malignancies, the results from the Cox 
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proportional hazard model were not significant.  
    Another limitation is the fact that not all states are SEER registered which means that the 
data did not include all areas within the United States. For this study, only 17 regions were 
included in the Non-Kentucky SEER group and then Kentucky was included separately in the 
analysis. Due to the fact that not all states are SEER registered, this makes the analysis limited in 
the implications when applying it to other areas or other populations as a whole.  
    When studying multiple primary and synchronous cancers cases, there must be a high 
level of accuracy in tumor registration. Even studies that used data sets that were well known to 
be of very high quality were at times found to contain errors that affected interpretation 
substantially.11 The classification of multiple primary tumors is incredibly difficult. In addition to 
this, there is lack of agreement on a standard definition for multiple primary cancers and this 
causes a great amount of confusion among researchers.11  In order to avoid this, other studies 
have eliminated potential sources of error by limiting the analysis to histologically confirmed 
tumors or tumors of a specific cell type (e.g., adenocarcinomas, endometrioid carcinoma), or by 
defining additional exclusion criteria (e.g., excluding synchronous tumors with similar histology 
types) to avoid the possibility of misclassified or misdiagnosed tumors.4,5 Even with strict 
guidelines to follow, there is still the chance that cancer cases that there were classified as a 
multiple primary case were done so falsely. This misclassification can potentially lead to 
misinterpretation of results.  
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Implications 
 When adjusting for early stage of disease, there were significant differences between 
Kentucky and SEER with regards to risk of developing early stage multiple primary 
malignancies but only within the logistic regression model. There were a greater proportion of 
early stage multiple primary cancers and synchronous within Kentucky when compared to Non-
Kentucky SEER. As previously mentioned be due to the Ovarian Cancer Screening Program 
Trial that has been ongoing since 1987 at the University of Kentucky. The screening program’s 
use trans-vaginal sonography along with serum CA-125 testing has proved to be incredibly 
effective for earlier detection of ovarian cancer 33,35. Our study demonstrates the importance of 
early detection in ovarian cancer in that more than two-thirds of asymptomatic women with 
ovarian cancer detected by screening in the 2011 trial at the University of Kentucky presented 
with localized disease at the time of cancer detection, and the 5-year survival rate for these 
patients was nearly 90%. Without early detection, most of these women will likely go on to 
present with later stage of disease which ultimately increases cost of treatment and decreases the 
average cure rate.36 Interestingly, this screening method has not produces any survival 
differences between early stage multiple primary or synchronous ovarian cancer cases within 
Kentucky. The cause of this is most likely the fact that annual trans-vaginal sonography is not 
currently recommended within the guidelines for ovarian cancer prevention. The reasoning for 
this is that currently there is no evidence that any screening test, CA-125, ultrasound, or pelvic 
examination, has reduced overall mortality from ovarian cancer. Additionally, despite the 
existing evidence that these screening methods can detect ovarian cancer in earlier stages is not 
enough evidence to demonstrate that these earlier diagnoses will reduce mortality. Furthermore, 
the use of trans-vaginal sonography has some drawbacks including the invasive nature of the 
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screening method and the higher rates of false diagnoses of ovarian cancers especially in women 
who are only at moderate risk for the disease.23 
   It is also important to note that over the past few years, multiple primary cancer cases have 
been decreasing. The overall trend in this study for multiple primary cancers shows a decrease in 
cases as the years increase from 2000-2014. These patients are diagnosed in earlier years which 
means that they were more likely to develop other cancers simply because they survived longer 
and had more opportunity to do so. For synchronous cancers cases, the number of cases 
decreased as the years went on from 2000-2014. This could be due to better screening and 
diagnosis methods. The Cox regression model for multiple primary cancers shows that the odds 
ratio for year of diagnosis increased which also indicates an increase in synchronous cancers in 
the more recent years. This indicates that most of these women who are being screened recently, 
are most likely having their cancers diagnosed due to better screening methods and increase in 
overall surveillance over the past few years. These advances in screening methods do have 
clinical implications for future health care needs. As the population increases and survival 
increases for these patients, their medical care needs will morph over time. For future analyses, is 
important to examine long-term treatment effects on these patients and to be aware of the issues 
that impact multiple primary and synchronous cancer patients. The population of patients who 
are being treated for cancer is also aging, and projections for U.S. population suggest that they 
will continue to age through years to come. As a consequence, the patient population might have 
increased comorbidities that will affect both treatment decisions and healthcare options during 
survivorship.7 
         
27 
 
 Additionally, the results from the survival analysis for late stage cancer indicated that 
there is also still a gap for the care of late stage cancers within Kentucky. Compared to Non-
Kentucky SEER, late stage cancer multiple primary and synchronous ovarian cancer patients had 
much worse survival. Like many other cancers in Kentucky, this could be due to the lower socio-
economic areas in the state and a lack of access to care such as poor health insurance coverage. 
In one study conducted in 2003 on overall cancer survival in Kentucky, one major influence on 
survival was health coverage.18 Another study found that for most of the cancers that were 
studied, the patients from more deprived economic areas had poorer survival than those from 
more advantaged areas.17,22 
The focus of this study was not on late stage but early stage differences. To be able to determine 
what is likely associated with these differences in late stage survival, further analyses may be 
needed.  
Conclusion:  
    Even though adjusted logistic models revealed some differences between the Kentucky 
and Non-Kentucky SEER populations of ovarian cancer patients, the adjusted multivariable Cox 
proportional hazard analysis indicated that there were no differences between Kentucky and 
SEER patients regarding the development of multiple primary cancers. This study did provide 
insight as to potential risk factors for development of multiple and synchronous cancers in 
ovarian cancer patients. High risk groups identified in this study are women who were diagnosed 
in earlier years, were older, white, single, lived in an urban area, had grade I cancer, and those 
who had sex chord-stromal tumors. Due to the results from the Cox Regression model, further 
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investigation is needed to determine definitively the implications of more  early stage cancer 
within Kentucky.  
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Tables and Figures 
Table 1. Descriptive statistics for all cases in Kentucky and SEER (N=72,491) 
 
 
 
Kentucky 
 
 
 
Non-Kentucky SEER 
 
 
 
 
 
Variable 
 
 
 
 
(3671, 5.06%) 
 
 
 
(68,820, 94.93%) 
P-value 
Age at diagnosis (years)    
 
 
0.0197 
20-49 718 (19.6%) 14008 (20.4%) 
50-64 1204 (32.8%) 23801 (34.6%) 
65-74 789 (21.5%) 14228 (20.7%) 
75+ 960 (26.2%) 16783 (24.4%) 
   
Year of diagnosis    
 
 
 
 
 
 
 
0.0027 
2000 301 (8,2%) 4547 (6.6%) 
2001 248 (6.8%) 4687 (6.8%) 
2002 261 (7.1%) 4619 (6.7%) 
2003 234 (6.4%) 4557 (6.6%) 
2004 265 (7.2%) 4452 (6.5%) 
2005 248 (6.8%) 4567 (6.6%) 
2006 265 (7.2%) 4567 (6.6%) 
2007 240 (6.5%) 4585 (6.7%) 
2008 245 (6.7%) 4758 (6.9%) 
2009 234 (6.4%) 4638 (6.7%) 
2010 225 (6.1%) 4618 (6.7%) 
2011 235 (6.4%) 4560 (6.6%) 
2012 239 (6.5%) 4593 (6.7%) 
         
35 
 
2013 235 (6.4%) 4558 (6.6%) 
2014 196 (5.3%) 4630 (6.7%) 
    
Race    
 
 
 
<0.0001 
White 3496 (95.2%) 56888 (82.7%) 
Black 153 (4.2%) 5842 (8.5%) 
Other (American Indian/AK 
Native, Asian/Pacific Islander) 
15 (0.4%) 5786 (8.4%) 
Unknown 7 (0.2%) 304 (0.4%) 
    
*Appalachian Status (Kentucky)    
 
- Appalachian 1129 (30.8%) - 
Non-Appalachian 2542 (69.3%) - 
    
Urban/Rural    
 
 
<0.0001 
Urban 1967 (53.6%) 62077 (90.2%) 
Rural 1704 (46.4%) 6670 (9.7%) 
Unknown 0 (0.0) 73 (0.11) 
    
Marital Status at Diagnosis    
 
 
 
<0.0001 
Single 465 (12.7%) 12315 (17.9%) 
Married 1638 (44.6%) 33158 (48.2%) 
Separated/Divorced 367 (10%) 7403 (10.8%) 
Widowed 838 (22.8%) 13286 (19.3%) 
Unknown 363 (9.9%) 2658 (3.9%) 
    
Number of Primary    
 
0.4115 Single primary 3386 (92.2%) 63728 (92.6%) 
Multiple primary 285 (7.8%) 5092 (7.4%) 
    
Number of Cancer Diagnoses    
 
 
 
0.6082 
Single 3337 (90.9%) 62651 (91.0%) 
Synchronous 139 (3.9%) 2350 (3.4%) 
Non-synchronous 101 (2.8%) 1941 (2.8%) 
Unknown 94 (2.5%) 1878 (2.7%) 
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Synchronous Cancers    
 
0.2358 Synchronous 139 (3.9%) 2350 (3.4%) 
Non-synchronous/single primary 3438 (96.1%) 64592 (96.5%) 
    
Stage    
 
 
0.0280 
Early stage (I and II) 1061 (28.9%) 18715 (27.2%) 
Late stage (III and IV) 2014 (54.9%) 39260 (57.1%) 
Unknown 596 (16.2%) 10845 (15.8%) 
    
Grade    
 
<0.0001 I 250 (6.8%) 4433 (6.4%) 
II 508 (13.8%) 8310 (12.1%) 
III 1006 (27.4%) 20793 (30.2%) 
IV 498 (13.6%) 8461 (12.3%) 
Unknown 1409 (38.4%) 26823 (39%) 
    
Histologic Type ICD-O-3    
 
 
 
0.0051 
Epithelial tumors 2267 (61.8%) 44180 (64.2%) 
Sex chord-stromal tumors 285 (7.8%) 4599 (6.7%) 
Germ cell tumors 65 (1.8%) 1334 (1.9%) 
Unspecified/Others/Borderline 
tumors 
1054 (28.7%) 
 
18707 (27.2%) 
    
*For the variable Appalachian, descriptive statistics were only calculated for Kentucky due to the fact that only 2 
out of 16 regions included in the Non-Kentucky SEER group had Appalachian regions. 
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In the analysis for synchronous cancers, 1,972 observations were missing/deleted due to the fact that they 
did not have information on their date of second cancer diagnosis and could not be classified as 
synchronous or non-synchronous. 
Note: For this table, Unknown category for stage was not included for multiple and synchronous cancers. 
 
 
 
 
Table 2. Distribution of Multiple Primary and Synchronous Cancer by SEER and KY, 2000-2014 
  
 
KY SEER 
 
Variable  
N 
 
% 
 
N 
 
% 
p-value 
Multiple Primary 
Early Stage 
     
Single Primary 901 84.9% 16417 87.7% 0.0071 
Multiple Primary 160 15.1% 2298 12.3% 
Late Stage 
     
Single Primary 1911 94.9% 36995 94.2% 0.2176 
Multiple Primary 103 5.1% 2265 5.8% 
Synchronous Cancer 
Early Stage 
     
Non-sync/Single 957  92.6% 17269 93.9% 0.0950 
Sync Cancer 76 7.4% 1117 6.1% 
Late Stage 
     
Non-sync/Single 1948 97.4% 37810 97.4% 0.9267 
Sync Cancer 52 2.6% 996 2.6% 
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Table 3. Descriptive statistics of ovarian cancer patients by multiple primary cancer status (N=72,491) 
 
 
 
 
Kentucky 
 
 
  
Non-Kentucky SEER 
 
 
Variable Single 
 
 
 
(3337, 4.6%) 
Multiple 
 
(285, 0.39%) 
P-value Single 
 
 
 
(63728, 88.0%) 
Multiple 
 
(5092, 7.0%) 
P-value 
Age at diagnosis (years)       
20-49 645(19.0%) 73 (25.6%)  
 
<0.0001 
12765 (20.0%) 1243 (24.4%)  
 
<0.0001 
50-64 1089 (32.2%) 115 (40.4%) 21712 (34.1%) 2089 (41.0%) 
65-74 729 (21.5%) 60 (21.1%) 13201 (20.7%) 1027 (20.2%) 
75+ 923 (27.3%) 37 (13.0%) 16050 (25.2%) 733 (14.4%) 
       
Year of diagnosis       
2000 274 (8.1%) 27 (9.5%)  
 
 
 
 
 
 
 
0.0109 
4145 (6.5%) 402 (7.9%)  
 
 
 
 
 
 
 
<0.0001 
2001 234 (6.9%) 14 (4.9%) 4274 (6.7%) 413 (8.1%) 
2002 244 (7.2%) 17 (6.0%) 4248 (6.7%) 371 (7.3%) 
2003 217 (6.4%) 17 (6.0%) 4175 (6.6%) 382 (7.5%) 
2004 244 (7.2%) 21 (7.4%) 4093 (6.4%) 359 (7.1%) 
2005 224 (6.6%) 24 (8.4%) 4114 (6.5%) 337 (6.6%) 
2006 248 (7.3%) 17 (6.0%) 4164 (6.5%) 403 (7.9%) 
2007 215 (6.4%) 25 (8.8%) 4241 (67%) 344 (6.8%) 
2008 216 (6.4%) 29 (10.2%) 4398 (6.9%) 360 (7.1%) 
2009 205 (6.1%) 29 (10.2%) 4290 (6.7%) 348 (6.8%) 
2010 207 (6.1%) 18 (6.3%) 4333 (6.8%) 285 (5.6%) 
2011 223 (6.6%) 12 (4.2%) 4271 (6.7%) 289 (5.7%) 
2012 228 (6.7%) 11 (3.9%) 4307 (6.8%) 286 (5.6%) 
2013 220 (6.5%) 15 (5.3%) 4267 (6.7%) 291 (5.7%) 
2014 187 (5.5%) 9 (3.2%) 4408 (6.9%) 222 (4.4%) 
     
Race     
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White 3224 (95.2%) 272 (95.4%)  
 
 
0.8925 
52553 (82.5%) 4335 (85.1%)  
 
 
<0.0001 
Black 141 (4.2%) 12 (4.2%) 5505 (8.6%) 337 (6.6%) 
Other (American Indian/AK 
Native, Asian/Pacific Islander) 
14 (0.1%) 1 (0.4%) 5373 (8.4%) 413 (8.1%) 
Unknown 7 (0.2%) 0 (0.0%) 297 (0.5%) 7 (0.1%) 
     
*Appalachian Status (Kentucky)     
Appalachian 1036 (30.6%) 93 (32.6%)  
0.4746 
- -  
- 
Non-Appalachian 2350 (69.4%) 192 (67.4%) - - 
     
**Urban/Rural     
Urban 1809 (53.4%) 158 (55.4%)  
 
0.5129 
57445 (90.1%) 4632 (91.0%)  
 
0.1463 Rural 1577 (46.6%) 127 (44.6%) 6216 (9.8%) 454 (8.9%) 
Unknown 0 (0.0) 0 (0,0) 67 (0.1%) 6 (0.1%) 
       
Marital Status at Diagnosis     
Single 421 (12.4%) 44 (15.4%)  
 
 
0.0224 
11268 (17.7%) 1047 (20.6%)  
 
 
<0.0001 
Married 1510 (44.6%) 128 (44.9%) 30500 (47.9%) 2658 (52.2%) 
Separated/Divorced 329 (9.7%) 38 (13.3%) 6859 (10.8%) 544 (10.7%) 
Widowed 792 (23.4%) 46 (16.1%) 12621 (19.8%) 665 (13.1%) 
Unknown 334 (9.9%) 29 (10.2%) 2480 (3.9%) 178 (3.5%) 
       
Stage     
Early (I and II) 901 (26.6%) 160 (56.1%)  
 
<0.0001 
16417 (25.8%) 2298 (45.1%)  
 
<0.0001 Late (III and IV) 1911 (56.4%) 103 (36.1%) 36995 (58.1%) 2265 (44.5%) 
Unknown 574 (17.0%) 22 (7.7%) 10316 (16.2%) 529 (10.4%) 
     
Grade     
I 210 (6.2%) 40 (14.0%)  
 
 
<0.0001 
3789 (6.0%) 644 (12.7%)  
 
 
<0.0001 
II 438 (12.9%) 70 (24.6%) 7314 (11.5%) 996 (19.6%) 
III 913 (27.0%) 93 (32.6%) 19228 (30.2%) 1565 (30.7%) 
IV 466 (13.8%) 32 (11.2%) 7908 (12.4%) 553 (10.9%) 
Unknown 1359 (40.1%) 50 (17.5%) 25489 (40.0%) 1334 (26.2%) 
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Histologic Type ICD-O-3     
Epithelial tumors 2062 (60.9%) 205 (71.9%)  
 
 
<0.0001 
40400 (63.4%) 3780 (74.2%)  
 
 
<0.0001 
Sex chord-stromal tumors 252 (7.4%) 33 (11.6%) 4149 (6.5%) 450 (8.8%) 
Germ cell tumors 61 (1.8%) 4 (1.4%) 1279 (2.0%) 55 (1.1%) 
Unspecified/Others/Borderline 
tumors 
1011 (29.9%) 43 (15.1%) 17900 (28.1%) 807 (15.9%) 
       
*For the variable Appalachian, descriptive statistics were only calculated for Kentucky due to the fact that only 2 
out of 16 regions included in the Non-Kentucky SEER group had Appalachian regions. 
**For the variable urban, chi-square values had to be calculated without the unknown category within Kentucky 
due to the cells that had a value of zero. 
Table 4. Descriptive statistics of ovarian cancer patients by synchronous cancer status (N=70519) 
 
 
 
 
Kentucky 
 
 
  
Non-Kentucky SEER 
 
 
Variable Synchronous 
 
 
(139, 3.9%) 
Non-
synchronous 
(3438, 96.1%) 
P-value Synchronous 
 
 
(2350, 3.5%) 
Non-
synchronous 
(64592, 96.5%) 
P-value 
Age at diagnosis (years)    
 
0.0005 
   
 
<0.0001 
20-49 45 (32.4) 667 (19.4) 694 (29.5) 13079 (20.3) 
50-64 48 (34.5) 1131 (32.9) 922 (39.2) 22366 (34.6) 
65-74 23 (16.6) 745 (21.7) 406 (17.3) 13517 (20.9) 
75+ 23 (16.6) 895 (26.0) 328 (14.0) 15630 (24.2) 
       
Year of diagnosis       
2000 6 (4.3) 289 (8.4)  
 
 
 
 
 
 
 
0.0499 
132 (5.6) 4270 (6.6)  
 
 
 
 
 
 
 
<0.0001 
2001 5 (3.6) 239 (7.0) 140 (6.0) 4432 (6.9) 
2002 8 (5.8) 245 (7.1) 128 (5.5) 4326 (6.7) 
2003 5 (3.6) 225 (6.5) 143 (6.1) 4300(6.7) 
2004 7 (5.0) 250 (7.3) 138 (5.9) 4185 (6.5) 
2005 16 (11.5) 227 (6.6) 148 (6.3) 4167 (6.5) 
2006 7 (5.0) 254 (7.4) 156 (6.6) 4282 (6.6) 
2007 14 (10.1) 425 (6.3) 152 (6.5) 4294 (6.7) 
2008 11 (7.9) 224 (6.5) 158 (6.7) 4459 (6.9) 
2009 14 (10.1) 210 (6.1) 161 (6.9) 4365 (6.8) 
2010 12 (8.6) 204 (5.9) 161 (6.9) 4337 (6.7) 
2011 7 (5.0) 224 (6.5) 153 (6.5) 4285 (6.6) 
2012 7 (5.0) 225 (6.5) 170 (7.2) 4310 (6.7) 
2013 11 (7.9) 220 (6.4) 210 (8.9) 4244 (6.6) 
2014 9 (6.5) 184 (5.4) 200 (8.5) 4333 (6.7) 
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Race     
White 135 (97.1) 3271 (95.1)  
 
 
0.8594 
1974 (84.0) 53346 (82.6)  
 
 
0.0155 
Black 4 (2.9) 145 (4.2) 159 (6.8) 5507 (8.5) 
Other (American Indian/AK 
Native, Asian/Pacific Islander) 
0 (0.0) 15 (0.4) 210 (8.9) 5461 (8.5) 
Unknown 0 (0.0) 7 (0.2) 7 (0.3) 278 (0.4) 
     
*Appalachian Status (Kentucky)     
Appalachian  
47 (33.8) 
 
 
1048 (30.5) 
 
 
0.4036 
 
- -  
- 
Non-Appalachian  
92 (66.2) 
 
 
2390 (69.5) 
 
- - 
     
**Urban/Rural     
Urban 76 (54.7) 1842 (53.6)  
 
0.7990 
2158 (91.8) 58258 (90.2)  
 
0.0130 Rural 63 (45.3) 1596 (46.4) 192 (8.2) 6266 (9.7) 
Unknown 0 (0.0) 0 (0.0) 0 (0.0) 68 (0.1) 
Marital Status at Diagnosis     
Single 27 (19.4) 425 (12.4)  
 
 
0.0471 
575 (24.5) 11478 (17.8)  
 
 
<0.0001 
Married 65 (46.8) 1545 (44.9) 1167 (49.7) 31309 (48.5) 
Separated/Divorced 13 (9.4) 339 (9.9) 233 (9.9) 6903 (10.7) 
Widowed 27 (19.4) 776 (22.6) 284 (12.1) 12393 (19.2) 
Unknown 7 (5.0) 353 (10.3) 91 (3.9) 2509 (3.9) 
       
Stage     
Early (I and II) 76 (54.7%) 957 (27.8%)  
 
<0.0001 
1117 (47.5%) 17269 (26.7%)  
 
<0.0001 Late (III and IV) 52 (37.4%) 1948 (56.7%) 996 (42.4%) 37810 (58.5%) 
Unknown 11 (7.9%) 533 (15.5%) 237 (10.1%) 9513 (14.7%) 
     
Grade     
I 22 (15.8) 222 (6.5)  
 
 
<0.0001 
376 (16.0) 3978 (6.2)  
 
 
<0.0001 
II 40 (28.9) 456 (13.3) 546 (23.2) 7637 (11.8) 
III 43 (30.9) 948 (27.6) 585 (24.9) 19914 (30.8) 
IV 15 (10.8) 478 (13.9) 220 (9.4) 8130 (12.6) 
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Unknown 19 (13.7) 1334 (38.8) 623 (26.5) 24933 (38.6) 
     
Histologic Type ICD-O-3     
Epithelial tumors 102 (73.4) 2135 (62.1)  
 
 
0.0005 
1687 (71.8) 41831 (64.8)  
 
 
<0.0001 
Sex chord-stromal tumors 17 (12.2) 261 (7.6) 245 (10.4) 4277 (6.6) 
Germ cell tumors 1 (0.7) 63 (1.83) 20 (1.5) 1301 (98.5) 
Unspecified/Others/Borderline 
tumors 
19 (13.7) 979 (28.5) 398 (16.9) 17183 (26.6) 
*For the variable Appalachian, descriptive statistics were only calculated for Kentucky due to the fact that only 2 
out of 16 regions included in the Non-Kentucky SEER group had Appalachian regions. 
**For the variable urban, chi-square values had to be calculated without the unknown category due to the cells that 
had a value of zero. 
Table 5. Distribution of subsequent cancer sites for multiple primary and synchronous cancer in ovarian cancer 
patients 
  Kentucky   Non-Kentucky 
SEER 
    
Multiple Primary Cancers 
Cancer Site     P-value 
        
N=285 % N=2350 % 
Uterine 89 31.2 1322 56.3   
 
 
0.4992 
Breast 39 13.7 177 7.5  
Lung and Bronchus 14 4.9 57  2.4 
Ovary 13 4.6 69  1.4 
Other female genital 6 2.1 66  2.8 
Kidney and Renal Pelvis 5 1.8 58 2.5  
All Others 119  41.8 552  23.5 
Synchronous Cancers 
Cancer Site         P-value 
        
N=139 % N=2350 % 
Uterine 85 61.2 1322 56.3   
 
 
0.0443 
Ovary 10 7.2 118 5.0 
Breast 9 6.5 177 7.5  
Lung and Bronchus 7 5.0 57  2.4 
Other female genital 6 4.3 66  2.8 
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Kidney and Renal Pelvis 4 2.9 58 2.5  
All Others 18  12.9 552 23.5 
 
 
 
 
 
 
 
 
 
 
Figure 1. Kaplan Meier survival curves for multiple primary cases comparing SEER and Kentucky 
 
Log Rank-test: 0.7093 
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Figure 2. Kaplan Meier survival curves for early stage cancer in multiple primary cases comparing SEER 
and Kentucky 
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Log Rank test: 0.5805 
 
 
 
 
 
 
 
 
 
 
Figure 3. Kaplan Meier survival curves for late stage cancer in multiple primary cases comparing SEER 
and Kentucky  
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Log Rank test: 0.0329 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Kaplan Meier survival curves for synchronous cases comparing SEER and Kentucky 
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Log Rank test: 0.8419 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Kaplan Meier survival curves for early stage cancer in synchronous cases comparing SEER and 
Kentucky 
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Log Rank test: 0.9833 
 
 
 
 
 
 
 
 
 
 
Figure 6. Kaplan Meier survival curves for late stage cancer in synchronous cases comparing SEER and 
Kentucky 
         
49 
 
 
Log Rank test: 0.0353 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Logistic model for multiple primary cases adjusted for stage of disease 
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                                                                                    Early and Late Stage Early Stage Only 
Variable Adjusted 
OR 
95% CI P Adjusted  
OR 
95% CI P 
Location 
 
            Non-Kentucky SEER Areas 
            Kentucky 
 
 
 
Ref. 
1.06 
 
 
- 
(0.93, 1.22) 
 
 
- 
0.4008 
 
 
Ref. 
1.23 
 
 
- 
(1.02, 1.47) 
 
 
- 
0.0308 
Age at diagnosis (years) 
                
             20-49 
             50-64 
             65-74 
             75+ 
 
 
Ref. 
1.09 
1.06 
0.79 
 
 
- 
(1.01, 1.90) 
(0.96, 1.16) 
(0.70, 0.88) 
 
 
- 
<0.0001 
0.0080 
<0.0001 
 
 
Ref. 
1.06 
1.16 
0.86 
 
 
- 
(0.96, 1.18) 
(1.08, 1.33) 
(0.72, 1.03) 
 
 
- 
0.2144 
0.0046 
0.0068 
 
Year of diagnosis 
 
              2000-2014 
               
 
 
0.96 
 
 
(0.96, 0.97) 
 
 
<0.0001 
 
 
0.94 
 
 
(0.94, 0.96) 
 
 
<.0001 
 
Race 
White 
Black  
Other (American Indian/AK Native, 
Asian/Pacific Islander) 
Unknown 
 
 
Ref. 
0.76 
0.83 
 
0.27 
 
- 
(0.67, 0.87) 
(0.74, 0.93) 
 
(0.12, 0.60) 
 
- 
0.1260 
0.0244 
 
0.0051 
 
Ref. 
0.68 
0.76 
 
0.31 
 
- 
(0.56, 0.83) 
(0.65, 0.89) 
 
(0.13, 0.77) 
 
- 
0.6017 
0.1543 
 
0.0396 
Urban/Rural 
               
              Urban 
              Rural 
 
 
 
Ref. 
0.94 
 
 
- 
(0.85, 1.04) 
 
 
- 
0.2253 
 
 
Ref. 
0.94 
 
 
- 
(0.81, 1.08) 
 
 
- 
0.3915 
Marital Status at Diagnosis 
 
              Single 
              Married 
              Separated/Divorced 
              Widowed 
              Unknown 
 
 
Ref. 
0.89 
0.89 
0.83 
0.85 
 
 
- 
(0.82, 0.96) 
(0.80, 1.00) 
(0.73, 0.93) 
(0.72, 1.02) 
 
 
- 
0.9026 
0.9548 
0.0872 
0.5331 
 
 
Ref. 
0.85 
0.87 
0.82 
0.88 
 
 
- 
(0.76 0.95) 
(0.74, 1.02) 
(0.68, 0.98) 
(0.70, 1.11) 
 
 
- 
0.3725 
0.8136 
0.2704 
0.9751 
 
Grade 
Grade I  
Grade II 
Grade III  
Grade IV 
Unknown 
 
Ref. 
0.93 
0.69 
0.63 
0.54 
 
- 
(0.82, 1.02) 
(0.63, 0.77) 
(0.56, 0.72) 
(0.49, 0.61) 
 
- 
<0.0001 
0.0205 
<0.0001 
<0.0001 
 
Ref. 
0.94 
0.70 
0.58 
0.60 
 
 
 
- 
(0.83, 1.06) 
(0.61, 0.79) 
(0.48, 0.70) 
(0.53, 0.69) 
 
- 
<.0001 
0.1175 
0.0002 
<.0001 
Histologic Type ICD-O-3 
        
               Epithelial tumors 
               Sex chord-stromal tumors 
               Germ cell tumors 
               Unspecified/Others/Borderline tumors 
 
 
Ref. 
1.19 
0.32 
0.76 
 
 
- 
(1.07, 1.32) 
(0.24, 0.44) 
(0.69, 0.84) 
 
 
- 
<0.0001 
<0.0001 
0.5550 
 
 
Ref. 
1.06 
0.28 
0.72 
 
 
- 
(0.93, 1.22) 
(0.20 0.40) 
(0.61, 0.85) 
 
 
- 
<.0001 
<.0001 
0.4621 
CI, confidence interval; OR, odds ratio. 
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Table 7. Logistic model for synchronous cases adjusted for stage of disease 
 Early and Late Stage Early Stage Only 
Variable Adjusted 
OR 
95% CI P Adjusted  
OR 
95% CI P 
Location 
 
            Non-Kentucky SEER Areas 
            Kentucky 
 
 
 
Ref. 
1.14 
 
 
- 
(0.94, 1.38) 
 
 
- 
0.1949 
 
 
Ref. 
1.24 
 
 
- 
(0.96, 1.60) 
 
 
- 
0.1008 
 
Age at diagnosis (years) 
                
             20-49 
             50-64 
             65-74 
             75+ 
               
 
 
Ref. 
0.88 
0.73 
0.64 
 
 
- 
(0.78, 0.97) 
(0.64, 0.84) 
(0.55, 0.76) 
 
 
- 
0.0170 
0.0505 
<0.0001 
 
 
Ref. 
0.83 
0.67 
0.60 
 
 
- 
(0.72, 0.95) 
(0.54, 0.81) 
(0.47, 0.78) 
 
 
- 
0.1128 
0.0705 
0.0140 
 
Year of diagnosis 
 
              2000-2014 
               
 
 
1.03 
 
 
(1.02, 1.04) 
 
 
<0.0001 
 
 
1.03 
 
 
(1.01, 1.04) 
 
 
0.0003 
Race 
White 
Black  
Other (American Indian/AK Native, 
Asian/Pacific Islander) 
Unknown 
 
 
Ref. 
0.74 
0.90 
 
0.49 
 
- 
(0.61, 0.88) 
(0.77, 1.05) 
 
(0.22, 1.12) 
 
- 
0.8249 
0.1480 
 
0.1737 
 
 
Ref. 
0.58 
0.77 
 
0.56 
 
- 
(0.43 0.77) 
(0.63, 0.95) 
 
(0.23, 1.39) 
 
- 
0.2102 
0.5376 
 
0.5033 
 
Urban/Rural 
               
              Urban 
              Rural 
 
 
 
Ref. 
0.94 
 
 
- 
(0.81, 1.09) 
 
 
- 
0.3989 
 
 
Ref. 
0.91 
 
 
- 
(0.74, 1.12) 
 
 
- 
0.3737 
Marital Status at Diagnosis 
 
              Single 
              Married 
              Separated/Divorced 
              Widowed 
              Unknown 
 
 
 
Ref. 
0.75 
0.72 
0.74 
0.75 
 
 
- 
(0.68, 0.84) 
(0.61, 0.85) 
(0.63, 0.88) 
(0.59, 0.96) 
 
 
- 
0.2580 
0.1698 
0.3403 
0.6361 
 
 
Ref. 
0.77 
0.74 
0.69 
0.70 
 
 
- 
(0.67, 0.89) 
(0.59, 0.94) 
(0.53, 0.91) 
(0.50, 0.97) 
 
 
- 
0.9542 
0.6651 
0.2993 
0.4283 
Grade 
Grade I  
Grade II 
Grade III  
Grade IV 
Unknown 
 
 
Ref. 
0.92 
0.45 
0.39 
0.43 
 
- 
(0.80, 1.05) 
(0.39, 0.52) 
(0.33, 0.47) 
(0.37, 0.49) 
 
- 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
 
Ref. 
0.95 
0.51 
0.38 
0.47 
 
- 
(0.81, 1.11) 
(0.43, 0.62) 
(0.29, 0.49) 
(0.39, 0.56) 
 
- 
<0.0001 
0.0067 
<0.0001 
<0.0001 
Histologic Type ICD-O-3 
        
               Epithelial tumors 
               Sex chord-stromal tumors 
               Germ cell tumors 
               Unspecified/Others/Borderline tumors 
                
 
 
Ref. 
1.41 
0.20 
0.83 
 
 
- 
(1.23, 1.62) 
(0.12, 0.33) 
(0.72, 0.96) 
 
 
- 
<0.0001 
<0.0001 
0.0333 
 
 
Ref. 
1.18 
0.16 
0.66 
 
 
- 
(0.98, 1.41) 
(0.09, 0.29) 
(0.51, 0.85) 
 
 
- 
<0.0001 
<0.0001 
0.3861 
CI, confidence interval; OR, odds ratio. 
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Table 8. Cox proportional hazard model for multiple primary cases adjusted for stage 
 Early and Late Stage Early Stage Only 
Variable Adjusted 
HR 
95% CI P Adjusted  
HR 
95% CI P 
Location 
 
            Non-Kentucky SEER Areas 
            Kentucky 
 
 
 
Ref. 
1.06 
 
 
- 
(0.92, 1.22) 
 
 
- 
0.4330 
 
 
Ref. 
1.04 
 
 
- 
(0.91, 1.19) 
 
 
- 
0.6061 
 
Age at diagnosis (years) 
                
             20-49 
             50-64 
             65-74 
             75+ 
               
 
 
Ref.  
1.10 
1.15 
1.07 
 
 
- 
(1.02, 1.20) 
(1.05, 1.27) 
(0.95, 1.20) 
 
 
- 
0.0177 
0.0046 
0.2997 
 
 
Ref. 
1.14 
1.19  
1.05  
 
 
- 
(1.05, 1.23) 
 (1.08, 1.30) 
(0.94, 1.18) 
 
 
- 
0.0012 
0.0004 
0.3763 
Year of diagnosis 
 
              2000-2014 
               
 
 
1.02 
 
 
(1.01, 1.03) 
 
 
<0.0001 
 
 
1.03 
 
 
(1.02, 1.04) 
 
 
<0.0001 
Race 
White 
Black  
Other (American Indian/AK Native,  
Asian/Pacific Islander) 
Unknown 
 
 
Ref. 
0.84 
0.84 
0.34 
 
 
- 
(0.74, 0.95) 
(0.75, 0.95) 
(0.15, 0.75) 
 
 
 
 
- 
0.0079 
0.0048 
0.0076 
 
 
Ref. 
0.88 
0.86 
0.33 
 
 
- 
(0.78, 0.99) 
(0.77, 0.96) 
(0.16, 0.69) 
 
 
- 
0.0372 
0.0070 
0.0033 
Urban/Rural 
               
              Urban 
              Rural 
 
 
 
Ref. 
0.97 
 
 
- 
(0.88, 1.08) 
 
 
- 
0.5845 
 
 
Ref. 
0.96 
 
 
- 
(0.87, 1.06) 
 
 
- 
0.4488 
Marital Status at Diagnosis 
 
              Single 
              Married 
              Separated/Divorced 
              Widowed 
              Unknown 
 
 
 
Ref. 
0.83 
0.84 
0.84 
0.88 
 
 
 
- 
(0.76, 0.90) 
(0.74, 0.94) 
(0.74, 0.95) 
(0.73, 1.04) 
 
 
- 
<0.0001 
0.0036 
0.0060 
0.1381 
 
 
Ref. 
0.84 
0.86 
0.85 
0.88 
 
 
- 
(0.77, 0.91) 
(0.77, 0.97) 
(0.76, 0.96) 
(0.75, 1.03) 
 
 
- 
<.0001 
0.0098 
0.0068 
0.1105 
Grade 
Grade I  
Grade II 
Grade III  
Grade IV 
Unknown 
 
 
Ref. 
0.96 
0.69 
0.61 
0.62 
 
- 
(0.86, 1.07) 
(0.62, 0.77) 
(0.53, 0.69) 
(0.55, 0.69) 
 
- 
0.4540 
<0.0001 
<0.0001 
<0.0001 
 
Ref. 
0.96 
0.69 
0.60 
0.61 
 
- 
(0.86, 1.06) 
(0.63, 0.77) 
(0.53, 0.69) 
(0.55, 0.68) 
 
- 
0.4114 
<0.0001 
<0.0001 
<0.0001 
Histologic Type ICD-O-3 
        
               Epithelial tumors 
               Sex chord-stromal tumors 
               Germ cell tumors 
               Unspecified/Others/Borderline tumors                
 
 
Ref. 
1.17 
0.28 
1.02 
 
 
- 
(1.05, 1.30) 
(0.20, 0.40) 
(0.92, 1.12) 
 
 
- 
0.0055 
<0.0001 
0.7385 
 
 
Ref. 
1.13 
0.36 
1.03 
 
 
- 
(1.02, 1.26) 
(0.27, 0.48) 
(0.94, 1.13) 
 
 
- 
0.0195 
<0.0001 
0.5008 
CI, confidence interval; HR, hazard ratio. 
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Note: In the Cox regression analysis, there were only 55940 observations for the early/late stage group and only 18859 
observations used for early stage.  
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